- Mr David Oxley appointed as President – International
- Dr Johannes K Mühl appointed as Senior Vice President – Finance
Mr David Oxley appointed as President – International
David Oxley’s appointment extends the company’s reach to a growing network of global and regional strategic partners and international capital markets.
David brings more than twenty years professional experience to Exopharm, including complex, multi-product, cross-border licensing expertise, product candidate development and approval, commercialization, and capital markets. Within the biotech sector, David’s experience includes ten years of executive leadership responsibility within the regenerative medicine sector in China, Australia, and the US. Beyond the biotech sector, David has served on the board of directors of a private, antibody-based bioscience company along with a not-for-profit foundation focused on infectious diseases in Africa.
Prior to his tenure within the biotech sector, David served a combined eighteen years in executive leadership roles in the life sciences arena, including head of global sales and marketing and head of global government relations for medical devices companies, health-care capital markets management for a leading U.S. bank, policy advocacy before the U.S. Food and Drug Administration in addition to health-care legislative work for a Member of the United States Congress.
Mr. Oxley holds a bachelor’s degree from Portland State University and masters work from Johns Hopkins University.
Dr Johannes K Mühl appointed as Senior Vice President – Finance
Based in Zurich, Switzerland, Dr Johannes Mühl has joined Exopharm as Senior Vice President Finance. Johannes has a vast network in the life-science industry and is also a successful private investor in the biotech sector.
At Exopharm, Johannes is building the profile of the Company in the investment community and helping to shape Exopharm’s pipeline products and associated strategy and finance plan.
Johannes brings with him a wealth of transferable skills – analytical precision, deep understanding of Finance and Accounting across continents, deal making and thorough knowledge of the gene therapeutics and diagnostics market.
Previously, Johannes was International Head of Finance and Business Insights at Myriad Genetics where he co-led the organisation through a successful transformation with growth of top and bottom line. He has over 15 years of life-science industry finance experience with roles in Pfizer and Zimmer Biomet.
Johannes has a PhD from Edinburgh Napier University and is a Fellow of the Institute of Public Accountants (FIPA) Australia. Johannes also has a Diploma of International Business Administration from Furtwangen University and is currently studying towards a Master of Public Health at the University of Zurich.
David and Johannes report to Founder & CEO, Dr Ian Dixon.
“We welcome David and Johannes to the organization as we transition into a global exosome medicines company and engage international investors, payers, strategic partners and other stakeholders,” said Dr Dixon.
Company and Media Enquiries:
Dr Ian Dixon, MBA
Founder and Managing Director
P: +61 (0)3 9111 0026
Tel: +61 (0)411 402 737
Exopharm (ASX:EX1) is a clinical-stage biopharmaceutical company using exosomes to deliver a new class of transformative medicines funded with near-term revenue generated via partnerships and technology licensing.
As nature’s delivery platform for DNA, RNA, and proteins, exosomes are highly differentiated from synthetic drug delivery systems such as lipid nanoparticles (LNPs). The drug delivery industry is growing at an annual growth rate (CAGR) of 5% and currently valued at around US$175 billion.
Exosomes are an alternative means of drug delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell penetrating peptides, viral vectors and liposomes. In some uses, exosomes have superiority, including delivering DNA and other medicines into the nucleus of the cell, as is required for the rapidly advancing gene therapy market.
Exopharm’s LEAP technology solves the challenge of purifying clinical-grade exosomes at large scale and low cost.
Exopharm also has two exclusive proprietary technologies that allow advanced customisation of exosomes – the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types.
Exopharm uses variations and combinations of LOAD and EVPS to enable its biopharma partners to improve delivery of their drug candidates and help them design and test new exosome medicines aimed at treating a wide scope of medical problems including neurological disease, infectious disease, cancer, and fibrosis.
FORWARD LOOKING STATEMENTS
This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as ‘intends’, ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘aims’, ‘plans’ or ‘expects’. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm’s control or subject to the success of the Development Program.
Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.